Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by yorgosGKon May 15, 2018 8:45am

95 Views

Post# 28031298

RE:running out of cash

Your just a short who played the PP, there is literally no other reason to bash KALY. And based on your credibility its the equivilant of hearing it from a 4 year old. The company is short on cash, but if you haven't noticed, is continuing there day-to-day. That's because there will be a significant value added event in regards to financing (in addition to the GW FDA approval) that will put us in the clear of anything financing (and then some). Rob isn't allowed to top up on shares or he would at this opportunity because he's working on something. Don't be a goof and actually think KALY is ever going back to these prices lol. Just cover your short position and move on.

Bullboard Posts

Opawica seeks drill permits for Bazooka Gold Targets in Abitibi